Phosphorylated EGFR at tyrosine 1173 correlates with poor prognosis in oral squamous cell carcinomas

Oral Diseases

Volumn 20, Issue 2, 2014, Pages 178-185

  Monteiro, L S ^a   Ricardo, S ^b   Delgado, M L ^b   Garcez, F ^b   do Amaral, B ^a,c   Lopes, C ^d  

^a INSTITUTO DE INVESTIGAÇÃO E FORMAÇÃO AVANÇADA EM CIÊNCIAS E TECNOLOGIAS DA SAÚDE   (Portugal)

^b Instituto Politécnico de Saúde do Norte   (Portugal)

^c HOSPITAL DE SANTO ANTÓNIO   (Portugal)

^d UNIVERSITY OF PORTO   (Portugal)

Author keywords

EGFR; Oral cancer; PEGFR; Prognosis; Tissue microarray

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; TYROSINE;

ADULT; AGED; BIOSYNTHESIS; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; MORTALITY; MOUTH TUMOR; PHOSPHORYLATION; PROGNOSIS; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; PHOSPHORYLATION; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SURVIVAL RATE; TYROSINE;

EID: 84893804875     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/odi.12087     Document Type: Article

References (40)

1. Agra IM, Carvalho AL, Pinto CA et al (2008). Biological markers and prognosis in recurrent oral cancer after salvage surgery. Arch Otolaryngol Head Neck Surg 134: 743-749.
2. Ang KK, Berkey BA, Tu X et al (2002). Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62: 7350-7356.
3. Aquino G, Pannone G, Santoro A et al (2012). pEGFR-Tyr 845 expression as prognostic factors in oral squamous cell carcinoma: a tissue-microarray study with clinic-pathological correlations. Cancer Biol Ther 13: 967-977.
4. Atkins D, Reiffen KA, Tegtmeier CL, Winther H, Bonato MS, Störkel S (2004). Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 52: 893-901.
5. Bànkfalvi A, Piffkò J (2000). Prognostic and predictive factors in oral cancer: the role of invasive tumour front. J Oral Pathol Med 29: 291-298.
6. Barnes L, Everson JW, Reichart P, Sidransky D (2005). World health organization classification of tumours: pathology and genetics of head and neck tumours. IARC Press: Lyon, France, pp. 164-175.
7. Bonner JA, Harari PM, Giralt J et al (2006). Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354: 567-578.
8. Chen IH, Chang JT, Liao CT, Wang HM, Hsieh LL, Cheng AJ (2003). Prognostic significance of EGFR and Her-2 in oral cavity cancer in betel quid prevalent area. Br J Cancer 89: 681-686.
9. Ch'ng S, Low I, Ng D et al (2008). Epidermal growth factor receptor: a novel biomarker for aggressive head and neck cutaneous squamous cell carcinoma. Hum Pathol 39: 344-349.
10. Christensen ME, Engbaeck F, Therkildsen MH, Bretlau P, Nexo E (1995). A sensitive enzyme-linked immunosorbent assay used for quantitation of epidermal growth factor receptor protein in head and neck carcinomas: evaluation, interpretations and limitations. Br J Cancer 72: 1487-1493.
11. Cohen EE, Davis DW, Karrison TG et al (2009). Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol 10: 247-257.
12. Dhomen NS, Mariadason J, Tebbutt N, Scott AM (2012). Therapeutic targeting of the epidermal growth factor receptor in human cancer. Crit Rev Oncog 17: 31-50.
13. Downward J, Waterfield MD, Parker PJ (1985). Autophosphorylation and protein kinase C phosphorylation of the epidermal growth factor receptor. Effect on tyrosine kinase activity and ligand binding affinity. J Biol Chem 260: 14538-14546.
14. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (2010). American Joint Committee on Cancer: AJCC - Cancer Staging Manual. 7th edn. Springer: New York, pp. 1-40.
15. Filosto S, Becker CR, Goldkorn T (2012). Cigarette smoke induces aberrant EGF receptor activation that mediates lung cancer development and resistance to tyrosine kinase inhibitors. Mol Cancer Ther 11: 795-804.
16. Hahn WC, Weinberg RA (2002). Rules for making human tumors cells. N Engl J Med 347: 1593-1603.
17. Hama T, Yuza Y, Saito Y et al (2009). Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma. Oncologist 14: 900-908.
18. Harsha HC, Jimeno A, Molina H et al (2008). Activated epidermal growth factor receptor as a novel target in pancreatic cancer therapy. J Proteome Res 7: 4651-4658.
19. Hiraishi Y, Wada T, Nakatani K, Negoro K, Fujita S (2006). Immunohistochemical expression of EGFR and pEGFR in oral squamous cell carcinomas. Pathol Oncol Res 12: 87-91.
20. Kanematsu T, Yano S, Uehara H, Bando Y, Sone S (2003). Phosphorylation, but not overexpression, of epidermal growth factor receptor is associated with poor prognosis of non-small cell lung cancer patients. Oncol Res 13: 289-298.
21. Keller J, Shroyer KR, Batajoo SK et al (2010). Combination of phosphorylated and truncated EGFR correlates with higher tumor and nodal stage in head and neck cancer. Cancer Invest 28: 1054-1062.
22. Khalil MY, Grandis JR, Shin DM (2003). Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer. Expert Rev Anticancer Ther 3: 367-380.
23. Kusukawa J, Harada H, Shima I, Sasaguri Y, Kaneyama T, Morimatsu M (1996). The significance of epidermal growth factor receptor and matrix metalloproteinase-3 in squamous cell carcinoma of oral cavity. Eur J Cancer Oral Oncol 32: 217-221.
24. Laimer K, Spizzo G, Gasti G et al (2007). High EGFR expression predicts poor prognosis in patients with squamous cell carcinoma of the oral cavity and oropharynx: a TMA-based immunohistochemical analysis. Oral Oncol 43: 193-198.
25. Magkou C, Nakopoulou L, Zoubouli C et al (2008). Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas. Breast Cancer Res 10: R49.
26. Miyawaki M, Hijiya N, Tsukamoto Y, Nakada C, Kawahara K, Moriyama M (2008). Enhanced phosphorylation of the epidermal growth factor receptor at the site of tyrosine 992 in esophageal carcinomas. APMIS 116: 1097-1106.
27. Monteiro LS, Diniz-Freitas M, Garcia-Caballero T, Forteza J, Fraga M (2010). EGFR and Ki-67 expression in oral squamous cell carcinoma using tissue microarray technology. J Oral Pathol Med 39: 571-578.
28. Monteiro LS, Diniz-Freitas M, Garcia-Caballero T, Warnakulasuriya S, Forteza J, Fraga M (2012). Combined cytoplasmic and membranous EGFR and p53 overexpression is a poor prognostic marker in early stage oral squamous cell carcinoma. J Oral Pathol Med 41: 559-567.
29. Nishioka T, Kim HS, Luo LY, Huang Y, Guo J, Chen CY (2011). Sensitization of epithelial growth factor receptors by nicotine exposure to promote breast cancer cell growth. Breast Cancer Res 13: R113.
30. Noordhuis MG, Eijsink JJ, Ten Hoor KA et al (2009). Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancer. Clin Cancer Res 15: 7389-7397.
31. O-charoenrat P, Rhys-Evans PH, Archer DJ, Eccles SA (2002). C-erbB receptors in squamous cell carcinomas of the head and neck: clinical significance and correlation with matrix metalloproteinases and vascular endothelial growth factors. Oral Oncol 38: 73-80.
32. Perisanidis C, Savarese-Brenner B, Würger T et al (2012). HCRP1 expression status is a significant prognostic marker in oral and oropharyngeal cancer. Oral Dis 19: 206-211.
33. Schlessinger J (2004). Common and distinct elements in cellular signaling via EGF and FGF receptors. Science 306: 1506-1507.
34. Schmitz S, Machiels JP (2010). Molecular biology of squamous cell carcinoma of the head and neck: relevance and therapeutic implications. Expert Rev Anticancer Ther 10: 1471-1484.
35. Störkel S, Reichert T, Reiffen KA, Wagner W (1993). EGFR and PCNA expression in oral squamous cell carcinomas-a valuable tool in estimating the patient's prognosis. Eur J Cancer B Oral Oncol 29: 273-277.
36. Temam S, Kawaguchi H, El-Naggar AK et al (2007). Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 25: 2164-2170.
37. Ueda S, Ogata S, Tsuda H et al (2004). The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas 29: e1-e8.
38. Ulanovski D, Stern Y, Roizman P, Shpitzer T, Popovtzer A, Feinmesser R (2004). Expression of EGFR and Cerb-B2 as prognostic factors in cancer of the tongue. Oral Oncol 40: 532-537.
39. Warnakulasuriya S (2009). Global epidemiology of oral and oropharyngeal cancer. Oral Oncol 45: 309-316.
40. Wiley HS (2003). Trafficking of the ErbB receptors and its influence on signalling. Exp Cell Res 284: 78-88.